282 related articles for article (PubMed ID: 37441729)
1. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study.
Chung Y; Katial R; Mu F; Cook EE; Young J; Yang D; Betts KA; Carstens DD
Ann Allergy Asthma Immunol; 2022 Jun; 128(6):669-676.e6. PubMed ID: 35247595
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2.
Carstens D; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Chung Y
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2150-2161.e4. PubMed ID: 37146880
[TBL] [Abstract][Full Text] [Related]
4. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
[No Abstract] [Full Text] [Related]
5. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
[TBL] [Abstract][Full Text] [Related]
6. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
[TBL] [Abstract][Full Text] [Related]
7. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
9. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
10. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
11. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
12. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
[No Abstract] [Full Text] [Related]
13. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Cameli P; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Menzella F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Benci M; Boarino S; Schroeder JW
Respir Res; 2023 May; 24(1):135. PubMed ID: 37210543
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
19. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study
Caruso C; Cameli P; Altieri E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Canonica GW; Centanni S; D'Amato M; Del Giacco S; De Michele F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Caminati M; Vultaggio A; Zullo A; Rizzoli S; Boarino S; Vitiello G; Menzella F; Di Marco F
Front Med (Lausanne); 2022; 9():950883. PubMed ID: 36117962
[TBL] [Abstract][Full Text] [Related]
20. Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma.
Smith JL; Chung Y; Barron J; Barlows T; Nepal B; Carstens D
J Asthma; 2024 Jun; 61(6):520-531. PubMed ID: 38054593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
